trial

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia

NCTId NCT04318977
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Active Not Recruiting
Enrollment 62 (actual)
Sponsored by University of Regensburg
Primary completion 2024-08-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
62 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-02-01
Primary completion
2024-08-14
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
high-frequency rTMSTBS

Sponsors

University of RegensburgLead Sponsor
University Hospital, AachenCollaborator
University Hospital OstravaCollaborator
Brno University HospitalCollaborator

Investigators

1
Berthold Langguth, MD, PhDStudy Chair

Sites

4 total
Brno, CzechiaOstrava, CzechiaAachen, GermanyRegensburg, Germany

Facts & assertions

4 sourced
Enrollment
62
Phase
NA
Primary Completion Date
2024-08-14
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
high-frequency rTMS
drug
TBS
drug
lead_sponsor
University of Regensburg
company
collaborator
University Hospital, Aachen
company
University Hospital Ostrava
company
indication
Schizophrenia
indication
Schizophrenia
indication
Negative Symptoms With Primary Psychotic Disorder
indication
investigator
Berthold Langguth, MD, PhD
person